Cost-Effectiveness Analysis of Parenteral Methotrexate for the
Treatment of Crohn's Disease

J 2021

Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease

MLCOCH, Tomas, Barbora DECKER a Tomáš DOLEŽAL

Základní údaje

Originální název

Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease

Autoři

MLCOCH, Tomas (203 Česká republika), Barbora DECKER (203 Česká republika, garant, domácí) a Tomáš DOLEŽAL (203 Česká republika, domácí)

Vydání

APPLIED HEALTH ECONOMICS AND HEALTH POLICY, CHAM, SPRINGER INTERNATIONAL PUBLISHING AG, 2021, 1175-5652

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.686

Kód RIV

RIV/00216224:14110/21:00121701

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s40258-020-00628-y

UT WoS

000606723700001

Klíčová slova anglicky

Parenteral Methotrexate; Crohn's Disease; Cost-Effectiveness Analysis

Štítky

14110516, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 12. 2021 09:15, Mgr. Tereza Miškechová

Anotace

V originále

Background Despite worldwide use of parenteral methotrexate (pMTX), health economic evidence for its use in Crohn's disease (CD) is limited. The low price of this generic drug has removed any commercial incentive to further invest in research. However, there is an unmet need for treatment of mild-to-moderate CD, since biological/targeted therapies are usually reserved for patients with more severe disease due to the higher costs of these treatments. Objective To evaluate the cost-effectiveness of pMTX compared to the standard of care (SOC, i.e., high doses of oral corticosteroids (hdCS) followed by gradual tapering) for the treatment of mild-to-moderate CD in the Czech Republic. Methods We developed a 3-year Markov model with a 1-week cycle length comprising five health states. The model projected quality-adjusted life-years (QALYs) and costs from the healthcare payers' perspective. Efficacy data were obtained from a systematic literature review of clinical trials and extrapolated using survival analysis. Results Over a 3-year time-horizon, pMTX yields additional 0.111 QALYs (1.798 vs. 1.687) at an additional cost of euro513 (euro3087 vs. euro2574), with an incremental deterministic (probabilistic) cost-effectiveness ratio of euro4627 (euro4742)/QALY, far below the willingness-to-pay (WTP) threshold (approximate to euro47,000/QALY). The probabilistic sensitivity analysis showed that the probability of pMTX being cost-effective was 100%. A one-way sensitivity and scenario analysis confirmed the robustness of the base-case result. Conclusion Parenteral MTX proved to be cost-effective in patients with mild-to-moderate CD. This is the first published cost-effectiveness analysis of pMTX for this indication. It also shows an example of a lack of valuation of generic therapy despite its cost-effectiveness and a clear benefit to the healthcare system.

Citovat

MLCOCH, Tomas, Barbora DECKER a Tomáš DOLEŽAL. Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease. APPLIED HEALTH ECONOMICS AND HEALTH POLICY. CHAM: SPRINGER INTERNATIONAL PUBLISHING AG, 2021, roč. 19, č. 4, s. 593-604. ISSN 1175-5652. Dostupné z: https://dx.doi.org/10.1007/s40258-020-00628-y.

@article{1773326,
   author = {Mlcoch, Tomas and Decker, Barbora and Doležal, Tomáš},
   article_location = {CHAM},
   article_number = {4},
   doi = {http://dx.doi.org/10.1007/s40258-020-00628-y},
   keywords = {Parenteral Methotrexate; Crohn's Disease; Cost-Effectiveness Analysis},
   language = {eng},
   issn = {1175-5652},
   journal = {APPLIED HEALTH ECONOMICS AND HEALTH POLICY},
   title = {Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease},
   url = {https://link.springer.com/article/10.1007/s40258-020-00628-y},
   volume = {19},
   year = {2021}
}

TY  - JOUR
ID  - 1773326
AU  - Mlcoch, Tomas - Decker, Barbora - Doležal, Tomáš
PY  - 2021
TI  - Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease
JF  - APPLIED HEALTH ECONOMICS AND HEALTH POLICY
VL  - 19
IS  - 4
SP  - 593-604
EP  - 593-604
PB  - SPRINGER INTERNATIONAL PUBLISHING AG
SN  - 11755652
KW  - Parenteral Methotrexate
KW  - Crohn's Disease
KW  - Cost-Effectiveness Analysis
UR  - https://link.springer.com/article/10.1007/s40258-020-00628-y
N2  - Background Despite worldwide use of parenteral methotrexate (pMTX), health economic evidence for its use in Crohn's disease (CD) is limited. The low price of this generic drug has removed any commercial incentive to further invest in research. However, there is an unmet need for treatment of mild-to-moderate CD, since biological/targeted therapies are usually reserved for patients with more severe disease due to the higher costs of these treatments. Objective To evaluate the cost-effectiveness of pMTX compared to the standard of care (SOC, i.e., high doses of oral corticosteroids (hdCS) followed by gradual tapering) for the treatment of mild-to-moderate CD in the Czech Republic. Methods We developed a 3-year Markov model with a 1-week cycle length comprising five health states. The model projected quality-adjusted life-years (QALYs) and costs from the healthcare payers' perspective. Efficacy data were obtained from a systematic literature review of clinical trials and extrapolated using survival analysis. Results Over a 3-year time-horizon, pMTX yields additional 0.111 QALYs (1.798 vs. 1.687) at an additional cost of euro513 (euro3087 vs. euro2574), with an incremental deterministic (probabilistic) cost-effectiveness ratio of euro4627 (euro4742)/QALY, far below the willingness-to-pay (WTP) threshold (approximate to euro47,000/QALY). The probabilistic sensitivity analysis showed that the probability of pMTX being cost-effective was 100%. A one-way sensitivity and scenario analysis confirmed the robustness of the base-case result. Conclusion Parenteral MTX proved to be cost-effective in patients with mild-to-moderate CD. This is the first published cost-effectiveness analysis of pMTX for this indication. It also shows an example of a lack of valuation of generic therapy despite its cost-effectiveness and a clear benefit to the healthcare system.
ER  -

MLCOCH, Tomas, Barbora DECKER a Tomáš DOLEŽAL. Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease. \textit{APPLIED HEALTH ECONOMICS AND HEALTH POLICY}. CHAM: SPRINGER INTERNATIONAL PUBLISHING AG, 2021, roč.~19, č.~4, s.~593-604. ISSN~1175-5652. Dostupné z: https://dx.doi.org/10.1007/s40258-020-00628-y.

Podrobný výpis o publikaci